About
Insulin formulation to treat intestinal malabsorption
Areas of Focus
Categories
Biologics & BiopharmaceuticalMiddle East
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
5
As Collaborator
0
Total Enrollment
755
By Phase
PHASE2: 2PHASE3: 2PHASE2/PHASE3: 1
By Status
TERMINATED: 3NOT_YET_RECRUITING: 1RECRUITING: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT05904626Lead Sponsor
Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA
PHASE2Not yet recruiting
60 participants
Started: Sep 30, 2025 · Completed: Jun 30, 2027
NCT05670951Lead Sponsor
Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants
PHASE3Recruiting
360 participants
Started: Feb 20, 2025 · Completed: May 31, 2029
NCT02865122Lead Sponsor
Safety and Efficacy Study in Infant With SBS
PHASE2/PHASE3Terminated
2 participants
Started: Mar 20, 2017 · Completed: Mar 22, 2018
NCT02510560Lead Sponsor
Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants
PHASE3Terminated
300 participants
Started: Oct 9, 2016 · Completed: Apr 25, 2018
NCT01093638Lead Sponsor
Oral Formulation of Insulin for Preterm Infants
PHASE2Terminated
33 participants
Started: Aug 31, 2010 · Completed: Jan 31, 2016
Locations (1)
Headquarters
Nazareth, Israel
Map
Loading map...